Simulated surgical-type cerebral biopsies from post-mortem brains allows accurate neuropathological diagnoses in the majority of neurodegenerative disease groups

Acta Neuropathologica Communications

Volumn 2, Issue 1, 2014, Pages

  King, Andrew ^a,b   Maekawa, Satomi ^c   Bodi, Istvan ^a,b   Troakes, Claire ^b,c   Curran, Olimpia ^a   Ashkan, Keyoumars ^a   Al Sarraj, Safa ^a,b,c  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Biopsy; Dementia; Neurodegeneration

Indexed keywords

BIOPSY; FRONTAL LOBE; HUMAN; NEURODEGENERATIVE DISEASES; PATHOLOGY; PROCEDURES; SENSITIVITY AND SPECIFICITY; TEMPORAL LOBE; TISSUE FIXATION;

BIOPSY; FRONTAL LOBE; HUMANS; NEURODEGENERATIVE DISEASES; SENSITIVITY AND SPECIFICITY; TEMPORAL LOBE; TISSUE FIXATION;

EID: 85048230338     PISSN: None     EISSN: 20515960     Source Type: Journal    
DOI: 10.1186/2051-5960-1-53     Document Type: Article

References (32)

1. Hu WT, Chen-Plotkin A, Arnold SE, et al.: Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease. Acta Neuropathol 2010, 120: 385-399. 10.1007/s00401-010-0723-9
2. Wu Y, Le W, Jankovic J: Preclinical biomarkers of Parkinson disease. Arch Neurol 2011, 68: 22-30. 10.1001/archneurol.2010.321
3. Hulette CM, Earl NL, Crain BJ: Evaluation of cerebral biopsies for the diagnosis of dementia. Arch Neurol 1992, 49: 28-31. 10.1001/archneur.1992.00530250032011
4. Pulhorn H, Quigley DG, Bosma JJ, et al.: Impact of brain biopsy on the management of patients with nonneoplastic undiagnosed neurological disorders. Neurosurgery 2008, 62: 833-837. 10.1227/01.neu.0000318168.97966.17
5. Warren JD, Schott JM, Fox NC, et al.: Brain biopsy in dementia. Brain 2005, 128: 2016-2025. 10.1093/brain/awh543
6. Josephson SA, Papanastassiou AM, Berger MS, et al.: The diagnostic utility of brain biopsy procedures in patients with rapidly deteriorating neurological conditions or dementia. J Neurosurg 2007, 106: 72-75. 10.3171/jns.2007.106.1.72
7. Schott JM, Reiniger L, Thom M, et al.: Brain biopsy in dementia: clinical indications and diagnostic approach. Acta Neuropathol 2010, 120: 327-341. 10.1007/s00401-010-0721-y
8. Wong SH, Jenkinson MD, Faragher B, et al.: Brain biopsy in the management of neurology patients. Eur Neurol 2010, 64: 42-45. 10.1159/000315032
9. Venneti S, Robinson JL, Roy S, et al.: Simulated brain biopsy for diagnosing neurodegeneration using autopsy-confirmed cases. Acta Neuropathol 2011, 122: 737-745. 10.1007/s00401-011-0880-5
10. McKeith IG, Dickson DW, Lowe J, et al.: Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 2005, 65: 1863-1872. 10.1212/01.wnl.0000187889.17253.b1
11. Alafuzoff I, Arzberger T, Al-Sarraj S, et al.: Staging of neurofibrillary pathology in Alzheimer's disease: a study of the BrainNet Europe Consortium. Brain Pathol 2008, 18: 484-496.
12. Ironside JW, Bell JE: The 'high-risk' neuropathological autopsy in AIDS and Creutzfeldt-Jakob disease: principles and practice. Neuropathol Appl Neurobiol 1996, 22: 388-393. 10.1111/j.1365-2990.1996.tb00908.x
13. Cairns NJ, Bigio EH, Mackenzie IR, et al.: Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the consortium for frontotemporal lobar degeneration. Acta Neuropathol 2007, 114: 5-22. 10.1007/s00401-007-0237-2
14. Kleinschmidt-De Masters BK, Prayson RA: An algorithmic approach to the brain biopsy--part I. Arch Pathol Lab Med 2006, 130: 1630-1638.
15. Prayson RA, Kleinschmidt-DeMasters BK: An algorithmic approach to the brain biopsy-part II. Arch Pathol Lab Med 2006, 130: 1639-1648.
16. Landis JR, Koch GG: The measurement of observer agreement for categorical data. Biometrics 1977, 33: 159-174. 10.2307/2529310
17. Al-Sarraj S, King A, Troakes C, et al.: p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS. Acta Neuropathol 2011, 122: 691-702. 10.1007/s00401-011-0911-2
18. Murray ME, Dejesus-Hernandez M, Rutherford NJ, et al.: Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. Acta Neuropathol 2011, 122: 673-690. 10.1007/s00401-011-0907-y
19. Rice CM, Gilkes CE, Teare E, et al.: Brain biopsy in cryptogenic neurological disease. Br J Neurosurg 2011, 25: 614-620. 10.3109/02688697.2010.551677
20. Hauw JJ, Duyckaerts C: Dementia, the fate of brain? Neuropathological point of view. C R Biol 2002, 325: 655-664. 10.1016/S1631-0691(02)01479-8
21. Javedan SP, Tamargo RJ: Diagnostic yield of brain biopsy in neurodegenerative disorders. Neurosurgery 1997, 41: 823-828. 10.1097/00006123-199710000-00011
22. Dwork AJ, Liu D, Kaufman MA, Prohovnik I: Archival, formalin-fixed tissue: its use in the study of Alzheimer's type changes. Clin Neuropathol 1998, 17: 45-49.
23. Pikkarainen M, Martikainen P, Alafuzoff I: The effect of prolonged fixation time on immunohistochemical staining of common neurodegenerative disease markers. J Neuropathol Exp Neurol 2010, 69: 40-52. 10.1097/NEN.0b013e3181c6c13d
24. Furukawa Y, Iseki E, Hino H, et al.: Ubiquitin and ubiquitin-related proteins in the brains of patients with atypical Pick's disease without Pick bodies and dementia with motor neuron disease. Neuropathology 2004, 24: 306-314. 10.1111/j.1440-1789.2004.00572.x
25. Kuusisto E, Kauppinen T, Alafuzoff I: Use of p62/SQSTM1 antibodies for neuropathological diagnosis. Neuropathol Appl Neurobiol 2008, 34: 169-180. 10.1111/j.1365-2990.2007.00884.x
26. Kuusisto E, Parkkinen L, Alafuzoff I: Morphogenesis of Lewy bodies: dissimilar incorporation of alpha-synuclein, ubiquitin, and p62. J Neuropathol Exp Neurol 2003, 62: 1241-1253.
27. Davidson YS, Raby S, Foulds PG, et al.: TDP-43 pathological changes in early onset familial and sporadic Alzheimer's disease, late onset Alzheimer's disease and down's syndrome: association with age, hippocampal sclerosis and clinical phenotype. Acta Neuropathol 2011, 122: 703-713. 10.1007/s00401-011-0879-y
28. Parchi P, Castellani R, Capellari S, et al.: Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol 1996, 39: 767-778. 10.1002/ana.410390613
29. Parchi P, Giese A, Capellari S, et al.: Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 1999, 46: 224-233. 10.1002/1531-8249(199908)46:2<224::AID-ANA12>3.0.CO;2-W
30. Lashley T, Rohrer JD, Bandopadhyay R, et al.: A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies. Brain 2011, 134: 2548-2564. 10.1093/brain/awr160
31. Neumann M, Rademakers R, Roeber S, et al.: A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain 2009, 132: 2922-2931. 10.1093/brain/awp214
32. Wagner JA: Biomarkers: principles, policies, and practice. Clin Pharmacol Ther 2009, 86: 3-7. 10.1038/clpt.2009.77